- Email: [email protected]
Allogeneic hematopoietic stem cell transplantation for myelofibrosis – one centre experience
acta haematologica polonica 44s (2013) 28–29
Contents lists available at SciVerse ScienceDirect
Acta Haematologica Polonica journal homepage: www.elsevier.com/locate/achaem
Wystąpienia ustne/Oral presentations
SESJA – Nowotwory mieloproliferacyjne Philadelphia ujemne (Ph-)
Wyróżnienie Komitetu Naukowego XXV Zjazdu PTHiT Allogeneic hematopoietic stem cell transplantation for myelofibrosis – one centre experience G. Helbig 1,**, A. Wieczorkiewicz-Kabut 1,*, L. Sedlak 2, T. Oleksy 2, M. Markiewicz 1, M. Kopera 1, S. Kyrcz-Krzemień 1 1 Department Of Hematology and Bone Marrow Transplantation, Silesian Medial University, Katowice, Poland 2 Student's Research Group, Department Of Hematology and Bone Marrow Transplantation, Silesian Medial University, Katowice, Poland *Presenting author. **Corresponding author. E-mail address: [email protected]
Introduction: Primary myelofibrosis (PMF) is characterized by clonal expansion of abnormal haematopoietic cells, bone marrow fibrosis, extramedullary hematopoiesis, anemia, splenomegaly and constitutional symptoms. Objectives: To evaluate the results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients treated for PMF in our clinic between 2008 and 2012. Material and Methods: We transplanted 21 PMF patients (10 male and 11 female) at median age of 49 years (range 19–63 years). Thirteen patients had JAK2V617F point mutation at transplant. Median time from diagnosis to allo-HSCT was 17.5 months (range 4.8–156 months). Sixty-six percent of patients had matched sibling donors. Reduced intensity conditioning (RIC) was used in 20 patients whereas one patient received myeloablative conditioning (MC). The sources of stem cells were following: peripheral blood (n = 16), bone marrow (n = 3) and blood and bone marrow (n = 2). All patients but one had chronic phase of PMF at the time of transplant. Results: Twenty patients engrafted. Absolute neutrophil count > 1 109/L and platelet count >50 109/L were achieved after a median of 15 days and 14 days, respectively. One patient died before engraftment due to brain hemorrhage. All evaluated patients had donor chimerism at day +30 after transplant. Complete eradication of JAK2V617F mutation was observed in nine patients (43%) whereas decrease of mutant burden was detected in four transplanted patients. Acute graft-versus-host disease (aGVHD) developed in 57% of patients and chronic GVHD in 52%. Relapse occurred in two patients with subsequent second transplant. After median follow-up of 18 months, four patients remained in complete remission and nine in partial remission according to IWG criteria. Eight patients (38%) died due to GVHD and infections. Conclusions: Allo-HSCT remains the only curative treatment for PMF; however, this procedure is associated with high risk of life-threatening complications. http://dx.doi.org/10.1016/j.achaem.2013.07.225
0001-5814/$ – see front matter
Contents lists available at SciVerse ScienceDirect
Acta Haematologica Polonica journal homepage: www.elsevier.com/locate/achaem
Wystąpienia ustne/Oral presentations
SESJA – Nowotwory mieloproliferacyjne Philadelphia ujemne (Ph-)
Wyróżnienie Komitetu Naukowego XXV Zjazdu PTHiT Allogeneic hematopoietic stem cell transplantation for myelofibrosis – one centre experience G. Helbig 1,**, A. Wieczorkiewicz-Kabut 1,*, L. Sedlak 2, T. Oleksy 2, M. Markiewicz 1, M. Kopera 1, S. Kyrcz-Krzemień 1 1 Department Of Hematology and Bone Marrow Transplantation, Silesian Medial University, Katowice, Poland 2 Student's Research Group, Department Of Hematology and Bone Marrow Transplantation, Silesian Medial University, Katowice, Poland *Presenting author. **Corresponding author. E-mail address: [email protected]
Introduction: Primary myelofibrosis (PMF) is characterized by clonal expansion of abnormal haematopoietic cells, bone marrow fibrosis, extramedullary hematopoiesis, anemia, splenomegaly and constitutional symptoms. Objectives: To evaluate the results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients treated for PMF in our clinic between 2008 and 2012. Material and Methods: We transplanted 21 PMF patients (10 male and 11 female) at median age of 49 years (range 19–63 years). Thirteen patients had JAK2V617F point mutation at transplant. Median time from diagnosis to allo-HSCT was 17.5 months (range 4.8–156 months). Sixty-six percent of patients had matched sibling donors. Reduced intensity conditioning (RIC) was used in 20 patients whereas one patient received myeloablative conditioning (MC). The sources of stem cells were following: peripheral blood (n = 16), bone marrow (n = 3) and blood and bone marrow (n = 2). All patients but one had chronic phase of PMF at the time of transplant. Results: Twenty patients engrafted. Absolute neutrophil count > 1 109/L and platelet count >50 109/L were achieved after a median of 15 days and 14 days, respectively. One patient died before engraftment due to brain hemorrhage. All evaluated patients had donor chimerism at day +30 after transplant. Complete eradication of JAK2V617F mutation was observed in nine patients (43%) whereas decrease of mutant burden was detected in four transplanted patients. Acute graft-versus-host disease (aGVHD) developed in 57% of patients and chronic GVHD in 52%. Relapse occurred in two patients with subsequent second transplant. After median follow-up of 18 months, four patients remained in complete remission and nine in partial remission according to IWG criteria. Eight patients (38%) died due to GVHD and infections. Conclusions: Allo-HSCT remains the only curative treatment for PMF; however, this procedure is associated with high risk of life-threatening complications. http://dx.doi.org/10.1016/j.achaem.2013.07.225
0001-5814/$ – see front matter